LifeSci Capital analyst Charles Zhu downgraded Mersana Therapeutics (MRSN) to Market Perform from Outperform after Day One Biopharmaceuticals (DAWN) agreed to buy the company for $25 per share in cash at closing plus one CVR worth up to an aggregate of $30.25 in cash.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSN:
- Hold Rating on Mersana Therapeutics Acquisition by Day One Biopharmaceuticals: Strategic Alignment and Risk-Adjusted Valuation
- Mersana Therapeutics downgraded to Market Perform from Outperform at Leerink
- Mersana Therapeutics downgraded to Hold from Buy at Truist
- Oppenheimer says Day One paying up to $285M for Mersana ‘is interesting’
- Mersana Therapeutics downgraded to Neutral from Buy at BTIG